Banco Bilbao Vizcaya Argentaria S.A. Sells 359 Shares of Axon Enterprise, Inc $AXON

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. has reduced its stake in Axon Enterprise by 17.2%, now holding 1,726 shares worth approximately $908,000.
• CEO Patrick W. Smith sold 10,000 shares of Axon for over $8.3 million, while insiders collectively sold 43,790 shares worth about $33.7 million in the last quarter.
• Axon Enterprise reported a strong earnings performance with a 32.6% revenue increase year-over-year, posting $2.12 EPS, beating analysts’ expectations of $1.54.

Banco Bilbao Vizcaya Argentaria S.A. lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 17.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,726 shares of the biotechnology company's stock after selling 359 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Axon Enterprise were worth $908,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. LaSalle St. Investment Advisors LLC grew its holdings in shares of Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock valued at $408,000 after purchasing an additional 16 shares during the last quarter. Pinion Investment Advisors LLC grew its stake in shares of Axon Enterprise by 3.0% during the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock worth $341,000 after buying an additional 19 shares during the last quarter. Kentucky Retirement Systems increased its holdings in shares of Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock worth $2,605,000 after buying an additional 19 shares in the last quarter. WCM Investment Management LLC lifted its stake in shares of Axon Enterprise by 0.8% in the 1st quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company's stock valued at $1,306,000 after acquiring an additional 19 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its holdings in shares of Axon Enterprise by 0.5% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 3,561 shares of the biotechnology company's stock valued at $1,873,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own 79.08% of the company's stock.

Wall Street Analyst Weigh In

AXON has been the subject of a number of recent research reports. Raymond James Financial reaffirmed an "outperform" rating and issued a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Wolfe Research initiated coverage on shares of Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating for the company. JMP Securities lifted their target price on shares of Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a research report on Tuesday, July 22nd. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. Finally, JPMorgan Chase & Co. raised their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Thirteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $837.69.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the sale, the chief executive officer directly owned 3,053,982 shares of the company's stock, valued at approximately $2,538,744,696.78. This trade represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,790 shares of company stock worth $33,654,451 over the last quarter. 5.70% of the stock is owned by company insiders.

Axon Enterprise Trading Up 0.2%

Shares of NASDAQ:AXON traded up $1.43 during trading on Wednesday, reaching $770.45. The stock had a trading volume of 219,055 shares, compared to its average volume of 698,889. Axon Enterprise, Inc has a 52 week low of $346.71 and a 52 week high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm's fifty day moving average is $772.54 and its 200 day moving average is $675.22. The stock has a market cap of $60.48 billion, a price-to-earnings ratio of 190.23, a P/E/G ratio of 28.02 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise's revenue for the quarter was up 32.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.